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Abstract
Problem: In 2017 the United States declared the opioid epidemic a public health emergency.
Since then, the opioid epidemic has been worsening and the rate of overdose deaths by drugs
has been rising. In 2020, 91,799 drug overdoses were reported compared to 70,630 overdose
deaths in 2019. Death by opioid and synthetic opioid overdose is prevalent among all racial and
ethnic groups, however, not all people have equal access to treatment. Buprenorphine is an
effective first-line medication for opioid use disorder that reduces the risk of overdose and
serious opioid related complications. People of color receive a significantly lower amount of
buprenorphine prescriptions than their White counterparts. Barriers contributing to the
inaccessibility of opioid use disorder treatment include clinic location, stigmatization,
prescription affordability, and lack of clinician cultural literacy.
Intervention: The focus of the project is to identify and address barriers that contribute to the
inaccessibility of buprenorphine at a Suboxone clinic and compare the identified barriers and
solutions provided by patients and staff to the literature. Barriers are identified based on the
experience of the clinic’s patients and staff.
Measure: Semi-structured interviews of patients and staff questionnaires were completed to
collect data regarding barriers and solutions to address said barriers.
Results: Barriers identified by the patients and staff that contribute to the inaccessibility of
buprenorphine by non-White patients at the buprenorphine clinic are consistent with barriers
expressed in the literature. These barriers include but are not limited to clinic location and
transportation, stigmatization, prescription affordability, and lack of clinician cultural literacy.
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Identifying and Addressing Racial Disparities at STEP’s Suboxone Clinic
The opioid crisis is a major public health problem that is devastatingly impacting the
lives of millions of people throughout the United States (Human and Health Services, 2020).
Opioids are invaluable short term treatment options for acute episodes of pain (Jones et al.,
2018). However, the over-prescription, misinformation of its addictive properties, and misuse
led the United States Government to declare the opioid epidemic a public health emergency in
2017 (Jones et al., 2018). Medication for opioid use disorder (MOUD), such as buprenorphine,
have been effective in reducing the risk of overdose and serious opioid related mortality
(Wakemen, 2020).
Although buprenorphine is effective in treating opioid use disorder (OUD), the majority
of patients receiving buprenorphine prescriptions are White. Buprenorphine use among
patients of color is significantly lower than their White counterparts. This is alarming because
the prevalence of opioid use disorder among non-White populations, especially Black and
Hispanic individuals, is high and increasing (Lagisetty et al., 2019). Barriers to MOUD access
have contributed to the low numbers of non-White patients who receive buprenorphine. These
barriers include buprenorphine clinic location, stigmatization, prescription affordability, and
clinician cultural literacy barriers.
The STEP Clinic, a buprenorphine clinic in Seattle WA, follows the nation’s trend of
serving a disproportionately low number of non-White patients with substance use disorder.
The purpose of this project is to identify and address racial disparities among non-White STEP
patients.
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Background
To understand treatment of opioid use disorder, the pathophysiology of OUD will briefly
be reviewed.
Pathophysiology of Opioid Use Disorder
The usage of opioids activates the mesolimbic pathways, also known as the pleasure
pathway, by attaching to the mu, kappa, and delta receptors. The attachment to the mu
receptors leads to dopamine release. Dopamine is a neurotransmitter that produces euphoric
and analgesic effects and is naturally released during exercise, sexual activity, and eating. The
usage of exogenous opioids leads to the release of an excessive amount of dopamine. Chronic
use of opioids causes the brain to require a greater amount of dopamine that cannot be
achieved without exogenous opioids resulting in an overpowering desire to use opioids (Brown
& Capili, 2020). The downregulation and the desensitization of the receptors result in opioid
tolerance and the sudden reduction or discontinuation of opioids cause withdrawal syndrome
(Shah, 2020). Those who experience withdrawal syndrome may experience physical symptoms
such as dilated pupils, diarrhea, generalized pain, and psychological symptoms such as anxiety
(Schuckit, 2016). The usage of opioids also disrupts the hypothalamic-pituitary-adrenal axis,
also known as the HPA axis, which controls the body’s response to stress (Brown & Capili,
2020). All these factors contribute to the extreme difficulty of overcoming opioid use disorder.
Fortunately, treatment is available to assist people in managing this chronic disorder. The paper
will focus on buprenorphine treatment.
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Mechanism of Action of Buprenorphine
Buprenorphine is a medication that is approved by the US Food and Drug Administration
for treatment of opioid use disorder (Coffa & Snyder, 2019). Buprenorphine is a partial mu
opioid receptor agonist that effectively prevents opioid withdrawal symptoms and significantly
reduces opioid cravings. Due to buprenorphine being a partial agonist, a ceiling effect is
reached which prevents it from being used for euphoric effect. Buprenorphine cannot be
displaced by full opioid receptor agonist, therefore limits the effects of opioids and heroin when
used after buprenorphine administration. Buprenorphine is prescribed in primary care settings.
Although follow up visits are mandatory for refills, daily visits are not required allowing patients
to pick up their prescription after a follow up visit and self-administer medication at their
desired location (Connery, 2015).
Effectiveness of Buprenorphine
Medication for opioid use disorder (MOUD) has been effective in reducing the risk of
overdose and serious opioid related mortality when compared to no treatment, opioid
antagonist therapy, inpatient treatment, and intensive outpatient behavioral interventions
(Wakeman, 2020). A 2018 retrospective cohort study found that opioid related mortality rates
decreased in half among adults who received either methadone or buprenorphine (Goedel et
al., 2020). Another study conducted on 40,885 adults with opioid use disorder who were
insured in Massachusetts between 2015 to 2017 compared the outcomes of adults who
received buprenorphine or methadone treatment to adults who received no treatment
(Wakeman, 2020). The study found that by three months of treatment, adults who received
buprenorphine or methadone had a 76% reduction rate in overdose and a 32% reduction rate
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in serious opioid related acute care use compared to no treatment. At 12 months, adults who
received buprenorphine or methadone had a 59% reduction rate in overdose and a 26%
reduction in serious opioid related acute care use compared to no treatment.
Literature Review
The search engines used to find scholarly publications were Google Scholar, PubMed,
and CINAHL. The terms used to conduct the searches were “people of color”, “POC”, “nonWhite”, “Suboxone”, “substance use disorder”, “opioid use”, “buprenorphine”, “barriers” and
“inaccessibility”. All publications reviewed and citied in this paper were within 7 years of
publication.
Prevalence
The United States Government declared the opioid epidemic a public health emergency
in 2017 due to over-prescription, misinformation of opioids addictive properties, and misuse
(Jones et al., 2018). Eight to 12% of people who are prescribed opioids develop an opioid use
disorder and four to six percent of people who misuse prescription opioids transition to heroin
use (National Institutes of Health, 2020). In 2018, drug overdose was the cause of 67,367
deaths in the United States (CDC, 2020). In Washington State, approximately 700 people die
from opioid overdose every year (National Institutes of Health, 2020). Projected trends show
that 700,000 more individuals will die of opioid-involved overdose in the next decade (Goedel
et al., 2020). Opioid use is the cause of other serious physical, mental, and social consequences
such as infections from injections, depression, homelessness, and stigmatization (McCarberg,
2015).
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The rate of opioid misuse and opioid-related overdose deaths have increased among
non-White people over the past years. In 2018, 1.2 million Black/African Americans were
estimated to have opioid misuse (Chau, 2020). Between 2015 to 2016, the overdose death rate
of Black/African Americans increased by 40% compared to the 21% increase in overdose death
rate of the overall population (Chau, 2020). From 2018 to 2019, Black/African Americans
experienced a 38% increase in deaths due to opioid overdose and between 2015 to 2017,
almost all ethnic and racial groups experienced a significant increase in deaths due from opioids
or synthetic opioids overdose (Larochelle et al., 2021 & Lippold et al., 2019). These rates
particularly increased among Black/African Americans in large central metro areas between the
ages of 45-54 years whose death rate increased from 19.3 to 41,9 per 100,000 and 55-64 years
whose death rate increased from 21.8 to 42.7 per 100,000 (Lippold et al., 2019).
Although OUD is prevalent among all racial/ethnic groups and effective treatment
options such as buprenorphine are available, the majority of treatment is received by White
patients. Non-White individuals are less likely than White individuals to encounter MOUD
prescribing physicians and receive MOUD (Gibbons, 2021; Hollander et al., 2021; Kilaru et al.,
2020). Lagisetty et al., (2019) combined data from the National Ambulatory Medical Care
Survey and the National Hospital Ambulatory Medical Care Survey from 2004 to 2015 to display
the race/ethnicity characteristics that are associated with office-based visits for buprenorphine
treatment in the United States. The study found that between 2012 and 2015, 12.7 million
buprenorphine prescriptions were received by White patients while only 363,000
buprenorphine prescriptions were received by other races/ethnicities. Figure 1, below,
illustrates buprenorphine visits by race/ethnicity between 2004-2015 and displays the
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significant increase of buprenorphine visits by White patients compared to the stagnantly low
buprenorphine visits of Black and other racial/ethnic patients. Hansen et al., (2016) found that
in New York City, buprenorphine treatment increased at a significantly higher rate in areas with
the highest incomes and lowest percentage of Black, Hispanic, and low-income residents while
Goedel et al., (2020) found the capacity to provide buprenorphine was higher in counties where
White residents did not interact with Black/African American and Hispanic/Latino residents.
Lack of access to MOUD can lead to detrimental consequences including death by overdose
(Madras et al., 2020).
Figure 1
Buprenorphine Visits by Race/Ethnicity and Payment Type, 2004-2015

Barriers to Obtaining Buprenorphine
Although opioid use disorder is prevalent among all racial/ethnic communities, nonWhite people are less likely to access buprenorphine (Lagisetty et al., 2019). Barriers
contributing to the inaccessibility of buprenorphine include but are not limited to, clinic
location, lack of clinician cultural literacy, stigmatization, and cost/insurance.
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Location of Buprenorphine Clinics
Goedel et al., (2020) conducted a nationwide population based cross sectional
geospatial analysis that found the capacity to provide methadone was higher in US counties
with a higher population density of Black/African Americans and Hispanics/Latino residents
who were unlikely to interact with White residents. Concurrently, the capacity to provide
buprenorphine was higher in counties with high density of White residents who were less likely
to interact with Hispanics/Latinos and Black/African American residents. These findings show
the serious inequities of access to MOUD based on the racialization of county lines (Goedel et
al., 2020).
Although methadone clinics are more accessible in counties with larger density of
Black/African Americans and Hispanic/Latinos, the disparity of buprenorphine clinics across
segregated counties is concerning and problematic (Goedel et al., 2020). Methadone clinics
place more restrictions on patients requiring daily dosage administration under clinician
supervision while buprenorphine is administered from home unsupervised and requires weekly,
biweekly, or monthly follow up visits. Regular methadone visits can be challenging for many
patients with substance use disorder due to creating burdens in managing jobs or other
obligations (Nolen, 2020). Methadone is also a highly stigmatized medication especially among
Black/African American communities compared to buprenorphine (Chau, 2020).

Cost/Insurance
Lack of healthcare insurance is another major factor that contributes to the
inaccessibility of buprenorphine since uninsured people are required to pay out-of-pocket for
MOUD (Martin, 2021). Hispanic/Latinos and Black/African Americans are more likely to be
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uninsured than Whites. In 2021, 23.6% of Hispanics/Latinos were uninsured and 11.8% of
Black/African Americans were uninsured, while 7.5% of Whites were uninsured (Yang, 2021).
Figure 2, below, illustrates this trend. The price of brand name buprenorphine/naloxone
sublingual films, Suboxone, can start from $293.18 for a quantity of 30 strips while the generic
buprenorphine/naloxone sublingual films can start from $102.14 for a quantity of 30 strips.
Buprenorphine tablet prices start at $27.86 for a quantity of 30 tablets (Martin, 2021). Some
health care providers direct patients to coupons that can significantly reduce costs.
Nonetheless, cost still remains a major factor for many uninsured patients. Although Medicaid
and the majority of private insurance covers buprenorphine, some healthcare providers remain
discouraged from participating in prescribing buprenorphine to Medicaid patients due to low
reimbursement rates (Miller, 2021).
Figure 2
Percentage of People Without Health Insurance in the US from 2010 to June 2021, by ethnicity

IDENTIFYING AND ADDRESSING RACIAL DISPARITIES

14

Clinician Cultural Literacy
Lack of clinician cultural literacy and respectful care towards patients of color with OUD
can cause early termination of treatment (Madras et al., 2020). Engaging in treatment for
opioid use disorder is difficult for all populations and is especially difficult for patients of color
who experience a lack of respect and empathy from their clinicians, whose cultural context is
misunderstood or ignored by clinicians, and in the context of a shortage of Black and Hispanic
buprenorphine prescribers (Chau, 2020). Language barriers further exacerbate the issue.
Patients whose primary language is not English may experience difficulty expressing their needs
or connecting with their healthcare provider (Psychiatry & Behavioral Health Learning Network,
2019).

Stigmatization
Stigma from the provider is another major barrier experienced by non-White patients.
Many clinicians, pharmacists, and staff have stigmatized attitudes towards people with
substance use disorder and towards MOUD (Madras et al., 2020). However, people of color
experience greater stigmatization due to their racial minority status, negative racial
representation, and racial stereotyping (SAMHSA, 2020). Providers may express stigmatization
towards patients with opioid use disorder by showing lack of empathy, less engagement, or by
believing patients to be violent, manipulative, or unmotivated (Madras et al., 2020).
Purpose of the Project
This project intends to address the racial disparities in buprenorphine treatment
experienced by non-White patients at a low barrier, harm reduction buprenorphine clinic in
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Seattle, WA called The STEP Clinic, also referred to as STEP. Details of The STEP Clinic are
discussed further below.
The STEP Clinic follows the nation’s trend of serving a disproportionate number of nonWhite patients. Figure 3, below, illustrates that as of March 1, 2020, 70.81% of The STEP Clinic’s
patient population are White while 12.57% are African American/Black, 6.68% are American
Indian, 3.91% are multiracial, and 1.70% are Asian. The remaining 1.85% of patients refused to
self-identify their race or ethnicity while 2.49% races/ethnicities are unknown. The data and
literature support a clear disparity of buprenorphine treatment among racial and ethnic
minorities.
The purposes of this project are to 1) collect information from non-White patients who
have previously received buprenorphine prescriptions from The STEP Clinic or are currently
receiving medication prescriptions from the STEP clinic to understand a) potential barriers that
cause them difficulties in receiving their buprenorphine prescription and b) feasible solutions
patients and staff believe the STEP clinic can implement to make it easier for non-White
patients to receive treatment at STEP, and; 2) to compare the collected data from staff and
patients to the literature to determine feasible solutions The STEP Clinic can implement to
remove barriers contributing to the inaccessibility of buprenorphine treatment and ultimately
increase enrollment and retention rate of non-White patients at The STEP Clinic who can
benefit from buprenorphine.
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Figure 3
STEP Clinic Demographic as of March 2020
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Note: The majority of STEP patients identified as White while a small minority of STEP patients
identified as other races/ethnicities.
Theoretical Framework
The theoretical framework that was implemented in this project is the Advancing
Research and Clinical Practice through Close Collaborations model. ARCC is used to provide
health care organizations and clinical settings with an organized conceptual framework that can
guide system-wide implementation and sustainability of evidence-based practice to achieve
quality outcomes. The model has five steps: 1) assessment of cultural organizational readiness
for implementation in the healthcare system, 2) identification of facilitators and barriers of the
EBP process in the organization, 3) identification of EBP mentors, 4) implementation of the
evidence into organizational practice, 5) evaluation of the outcomes resulting from the practice
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change (Rycroft-Malone & Bucknall, 2010). Figure 4, below, illiterates the five steps of the
ARCC model. The ARCC guided this project due to its reliance on clinical expertise provided by
STEP staff, patient preferences and values provided by STEP patients, and evidence-based
research provided by the literature. This project was able to assess the readiness of The STEP
Clinic by receiving approval and support to conduct the study. This project was also able to
achieve step 2 and step 3 but identifying barriers in the organization that contribute to the
inaccessibility of buprenorphine to non-White patients and identifying a facilitator, the author
of this project, to organize strategies to implement EBP practice in the clinic. Step 4 and 5 were
not achieved but the study encourages The STEP Clinic to complete the remaining steps.
Figure 4
ARCC Framework Steps for Implementing Evidence-Based Practice

Note: The image displays the five steps of the ARCC framework for implementing EBP at an
organization. This study was able to achieve the first three steps.
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Methods
This project is a quality improvement study with a pre-implementation analysis of
patient demographic (race/ethnicity). Data was collected from STEP patients and STEP staff
through semi-structured interviews and a questionnaire respectively to identify barriers
experienced by non-White patients at the STEP Clinic. Patients and staff who participated in this
study also suggested solutions that address the identified barriers.
Project Setting
This project was conducted at The STEP Clinic. STEP is an acronym for support,
treatment, engagement, and pride. The STEP Clinic is a low barrier, harm reduction clinic that is
partnered with the Hepatitis Education Program (HEP). The STEP Clinic’s mission is to improve
the health of the community by providing high quality, caring, culturally appropriate primary
health care that addresses patients’ needs regardless of ability to pay. Together, HEP and STEP
provide a variety of medical services including buprenorphine prescription for opioid use
disorder, syringe service program, vaccinations, infections disease testing including HIV,
Hepatitis C, and sexual transmitted infections, and provide hepatitis C management. The STEP
Clinic is located in the Central District neighborhood and is affiliated with a larger organization,
Country Doctor Community Clinic (Country Doctor Community Clinic, 2021).
Participants
Participants in this study were STEP patients who met the inclusion criteria and STEP
staff regardless of race/ethnicity. Patients eligible to participate in the study were patients of
The STEP Clinic who were receiving buprenorphine treatment or have previously received
buprenorphine treatment and identify as “Black/African America”, “American Indian/Alaska
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Native”, “Asian”, “Native Hawaiian/Other Pacific Islander”, “Multiracial”, “Hispanic”, or “Other”
under the racial/ethnic demographic in their Electronic Medical Record (EMR). Patients who
identified as “White”, “Unknown”, or “Refused to answer” were excluded from the study.
Patients who did not receive a buprenorphine prescription were also excluded from the study.
All staff of the STEP Clinic were eligible to participate in the study regardless of
race/ethnicity. This enables staff to report the barriers they have witnessed patients of color
experience at STEP and recommend solutions that address these barriers based on their own
expertise.
Patient Data Collection and Recruitment
An Excel sheet of all STEP patients who received care from the year 2020 to 2022 and
who did not identity as “White”, “Unknown”, or “Refuse to answer” was generated by the
Country Doctor Community Clinic’s (CDCC) EMR team and sent to the principal investigator (PI).
The PI reviewed the patients on the Excel sheet to ensure potential participants met inclusion
criteria. The PI deleted patients from the Excel sheet who did not receive a buprenorphine
prescription from STEP. Once the PI reviewed and confirmed that all patients met the inclusion
criteria, the PI began conducting semi-structured interviews at the PI’s private home using the
8X8 application. The 8X8 application allowed the PI to contact patients using CDCC’s phone
number to maintain the PI’s privacy. Each patient was contacted a maximum of three times.
Patients who did not answer after the third attempt were removed from the Excel sheet
provided by the EMR team. Each attempt to contact patients was completed during different
times of the day (morning, afternoon, evening) to accommodate patients’ work or school
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schedules. The PI did not leave voice messages to prevent traces of the study. Two weeks were
allotted to complete patient semi-structured interviews.
Once the PI successfully reached potential participants, the PI read the approved script
attached to the semi-structured interview form (Appendix A) explaining the purpose of the
study to patients. The PI then asked patients for verbal consent to participate. Once consent
was given, the semi-structured interview was conducted. Data collected from participants was
recorded on an Excel sheet. No direct patient identifiers (name, date of birth, medical record
number) were documented or attached to the collected data. Patients’ direct identifiers were
removed from the Excel sheet provided by the EMR team after the patients were either
successfully contacted or received three unsuccessful phone calls. All phone calls with patients
were completed by the PI. The Excel sheet provided by the EMR team was secured on the PI’s
password protected laptop. No monetary incentives were provided to participants.
Staff Data Collection and Recruitment
STEP staff were invited to participant in the study via CDCC primary distribution email. A
Google Form questionnaire (Appendix B) was attached to the email (Appendix C). Staff were
informed completing the questionnaire was optional. No staff identifiers (names, emails, phone
numbers) were documented or attached to the answers. Details of the study were provided in
the questionnaire. It was also stated that by answering and submitting the questionnaire, the
staff member was providing consent to participate in the study. The data of the participants
was organized in an Excel sheet. The PI holds sole access to the Google Form results of the
participants and the Excel sheet with the collected data. The Google Form and Excel sheet were
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secured on the PI’s password protected laptop. No monetary incentives were provided to
participants.
Instruments and Tools
The patient semi-structured interview (Appendix A) and staff questionnaire (Appendix
B) were created by the PI and reviewed and approved by the PI’s faculty advisor and site liaison.
They were designed to inquire participants about barriers typically experienced by non-White
patients who receive buprenorphine. Questions were based on barriers experienced by nonWhite patients found in the literature. Each instrument provided the opportunity for
participants to add additional information regarding their experience at The STEP Clinic.
Results
Eight patients completed the semi-structured interview, and eight STEP staff completed
the questionnaire. This is a qualitative study that utilized interviews and a questionnaire to
discuss participants’ opinions and perspectives; therefore, no quantitative test was needed to
analyze data. The PI reviewed participants’ answers and summarized the findings. Bar graphs
were created to improve ease of understanding the findings.
The findings from the patients and staff are summarized in Figure 5. The prevalence of
barriers reported varied between staff and patients. All staff identified at least one barrier
while two patients reported to have experienced no barriers when accessing their
buprenorphine at The STEP Clinic. “Stigmatization of patients by their own community” was
agreed upon unanimously by staff to be a barrier experienced by non-White STEP patients
while the most frequently reported barrier by patients was “other issues” which were reported
by 62.5% of patients. The least frequently reported barrier from staff was “mandatory
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appointments with the STEP provider”, which was reported by 50% of staff, while the least
frequently reported barriers from patients were “payment/insurance” and “clinic
environment/staff”. “Clinic environment/staff” was the barrier with the greatest incongruence
between staff and patients, with 87.5% of staff reporting this as a barrier while only 12.5% (one
patient) reporting to have experienced it as a barrier.
Figure 5
Barriers Experienced by Non-White Patients at The STEP Clinic Reported by Patients and Staff

Figure 5: The graph displays the percentages of participants who reported the categories as
barriers experienced by non-White patients at STEP. The red graphs represent the frequencies
these categories were reported by staff while the orange graphs represent the frequencies
these categories were reported by patients.
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STEP Staff Results
All staff unanimously agreed that patients who identify as non-White experience greater
barriers to accessing Suboxone at The STEP Clinic than their White counterparts.

Transportation and Clinic Location
Transportation and clinic location were reported to be challenges experienced by nonWhite patients when accessing their buprenorphine and services at STEP by 87.5% of staff. Two
staff participants reported that The STEP Clinic is located in a gentrified area and the majority of
STEP patients come from low-socioeconomic backgrounds and cannot afford to live within
walking distance of the clinic, therefore these patients have to take the public transit system.
The public transit system can be an inconvenience due to multiple transfers, long commute
hours, and the cost of fares. One staff participant reported the clinic is not connected to a good
transportation system that can be offered to patients who cannot walk or drive to the clinic.
This staff participant also noted that the clinic is not flexible in transitioning mandatory follow
up visits from in-person to phone visits to meet the needs of the patient population served.
Another staff participant reported the clinic should be located further south to be more
accessible to the targeted patient population.

Payment and Insurance
Seventy five percent of staff participants believe payment and insurance are challenges
experienced by non-White STEP patients. One staff participant reported that in general nonWhite people have greater rates of incarceration and insurance is suspended during the period
of incarceration. This can make it difficult for patients to cover their buprenorphine prescription
after release. The staff participant also noted that non-White patients have higher rates of
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being uninsured. The lack of healthcare coverage can cause their buprenorphine prescriptions
to be unaffordable.

Mandatory Appointments and Clinic Hours
Half of staff participants reported that mandatory appointments with the provider in
order to receive a buprenorphine prescription is a challenge to non-White patients while 62.5%
of staff participants reported that clinical hours are a barrier to suboxone. Staff participants did
not expand on barriers caused by mandatory appoints and clinic hours. However, three
participants reported that the urinary drug screens (UDS) during in-person visits acts as a
barrier to non-White patients. A participant noted that UDS results can cause patients to feel
judged, stigmatized, shame, and fear of discharge from the program or involvement of law
enforcement. Judgement and stigmatization are discussed in the sections below.

Clinical Environment and Staff
The clinic environment and staff were reported to be a barrier by 87.5% of staff
participants. Seven staff participants explained that the lack of non-White providers (physicians,
nurse practitioners, physician assistants) can create barriers to care. One staff participant noted
that non-White patients do not see themselves represented in the care team due to a majority
White staff, especially White providers. Another staff participant reported that White providers
cannot culturally relate to patients of color. Five staff participants highlighted that The STEP
Clinic is mostly a White space due to its predominantly White patient population and White
staff. Two staff participants explained this can make the clinic unwelcoming and uncomfortable
for patients of color.
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Several staff participants discussed judgment, distrust, and stigma from the STEP staff
experienced by non-White patients. One staff participant reported that Black patients are
scrutinized more heavily for substance use and for substances found in their UDS screenings
than their White counterparts. Two staff participants reported that concerns expressed by nonWhite patients are often not listened to. One staff participant reported that several Black
patients who expressed frustration with The STEP Clinic were dismissed or treated as “difficult.”
These patients also received shortened prescriptions due to concerns about other substance
use and were asked to come in for visits more frequently than other patients. This staff
participant reported these patients were monitored more closely than other patients in similar
situations. Another staff participant reported that non-White people may not seek care at STEP
due to fear of their healthcare provider involving law enforcement or taking a punitive
approach to their care compared to their White counterparts. One participant reported that
non-White patients, especially Black patients, are more often accused of divergence, which is
the unlawful distribution of prescribed medication from the person it was prescribed to another
person, and are not trusted by staff or providers. This staff participant noted The STEP Clinic is a
low-barrier clinic, therefore patients should not be tracked whether they take their medication
nor judged if they dispense their buprenorphine prescription or use other substances.

Stigmatization from Community
All staff participants reported that stigmatization of patients by family, friends, and
communities is a barrier experienced by non-White patients to accessing buprenorphine at The
STEP Clinic. One staff participate reported that they noticed patients from immigrant
communities tend to face greater stigma and less support from their family and friends than
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other non-White patients. Another staff participant reported that non-White patients often feel
judged and believe that people think of them as “drug addicts.” This staff participant reported
that often times, non-White patients will report to STEP staff their employment history or
educational background and explain that they are productive members of society who are
trying to do the right thing by receiving OUD treatment but feel that they experience extra
obstacles.

Pharmacy
Pharmacy issues were reported by 87.5% of staff participants to present challenges to
non-White patients in accessing buprenorphine. Four staff participants reported that nonWhite patients are judged or treated more poorly than their White counterparts when picking
up their buprenorphine prescription at certain pharmacies. One staff participant reported that
non-White patients frequently experience microaggression and racism at pharmacies. Examples
and scenarios were not provided. Another staff participant reported that pharmacy staff
request the ID of non-White patient when picking up their buprenorphine prescription more
often than their White counterparts. This staff participant also noted that non-White patients
are less likely to inform a nurse or provider when their prescription requires a prior
authorization to be filled and will instead fill the lower dose that does not require the additional
steps.

Other Issues
Finally, 87.5% of staff participants reported that there are other issues that present
challenges to non-White patients in accessing buprenorphine. Two staff participants reported
historical trauma: general mistrust of medical providers due to historical treatment and trauma
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of people of color. Four staff participants reported that systemic racism created barriers for all
non-White people in accessing all medical and social services including The STEP Clinic. Two
staff participants reported cultural and language barriers. One of these staff participants
explained that there is not enough literature about The STEP Clinic’s services in other languages
and that STEP services are not easy to navigate for non-English speakers. Two staff participants
also noted that there is not enough discussion at the clinic among staff about cultural
competency. Another staff participant reported that there is a lack of culturally relevant and
appropriate counseling support for non-White patients. One staff participant reported that
obtaining buprenorphine is a complicated and tedious process especially when racial barriers
experienced by non-White STEP patients are not taken into consideration. Five staff
participants reported a lack of outreach, community awareness of STEP services, and
collaboration with other organizations that center non-White communities and populations.
Two staff participants reported internalized shame experienced by patients is a challenge and
one staff participant noted past negative experience with medical services and medical
providers can create barriers to accessing treatment at STEP.
STEP Patient Results
This section will address the results of the patients’ semi-structured interview (Appendix
A). Eight out of forty-three eligible patients participated in this study. When patients were
asked about barriers to buprenorphine that they experienced at The STEP clinic, they
responded with varying degrees (Figure 5). Six patients reported to have experienced at least
one barrier contributing to the inaccessibility of buprenorphine at The STEP Clinic while two
patients reported to have experienced no barriers at The STEP Clinic. All patients who
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participated in this study reported they would recommend The STEP Clinic to other community
members.

Transportation and Clinic Location
Transportation and location of the clinic were reported as barriers by 25% of the patient
participants. Six of the patient participants reported they either lived close to the clinic or used
to live close when they received STEP services. The two patient participants who reported
transportation and location of the clinic as an issue have established care elsewhere due to the
distance of the clinic from their home and the inconvenience of the public transit system.

Payment and Insurance
One patient participant (12.5%) reported that insurance was a barrier to accessing their
buprenorphine prescription. The patient participant did not expand on their experience.

Mandatory Appointments and Clinic Hours
Half of patient participants reported that mandatory appointments and clinic hours
were barriers to receiving care at the STEP Clinic. Two patient participants explained they had
difficulties accommodating childcare therefore struggled to make in-person follow up visits to
obtain a buprenorphine prescription. One patient participant reported the limited hours and
clinic days made it difficult to obtain a buprenorphine prescription due to clinic hours coinciding
with work schedule. Another patient participant found the in-person visits were a hassle and
unnecessary.

Clinical Environment and Staff
One patient reported that the clinic’s environment and staff were barriers to their
treatment at the STEP Clinic. The patient participant felt mistreated by staff. The remaining
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87.5% who were interviewed reported that they felt very supported and welcomed by staff.
Four patient participants believed that the STEP staff were very committed to their patients’
care. Three patient participants felt welcomed to walk into the clinic at all times. One patient
participant stated the STEP staff were very knowledgeable and provided them with great
medical resources when transitioning care to another state. Another patient reported that nonWhite people usually don’t feel welcomed in a predominantly White space, however the STEP
staff made the participant feel very cared for.

Stigmatization from Community
Half of the patient participants reported that stigmatization from family, friends, and
communities are a barrier for non-White patients in accessing their buprenorphine prescription
at The STEP Clinic. One patient participant reported they withheld informing family and friends
about their opioid use disorder history and buprenorphine treatment to avoid judgement.
Another patient reported that only one family member is aware of their opioid use disorder and
buprenorphine treatment.

Pharmacy
Pharmacy issues were reported by 25% of participants as being barriers to
buprenorphine access. These patients reported to have experienced challenges at pharmacies
when attempting to fill their buprenorphine prescription. Two patient participants reported to
have faced poor treatment by pharmacy staff when attempting to fill buprenorphine. Both
patient participants switched pharmacies.
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Other Issues
Finally, 62.5% of patient participants reported that there are other issues that present
challenges to accessing buprenorphine. Three patient participants stated that internalized
shame from missing appointments or not adhering to buprenorphine make it difficult to return
to the clinic. One patient participant expressed disappointment in self and reported that the
STEP team spent a lot of time in developing a personalized plan, therefore when the participant
missed a couple of appointments, the participant felt too ashamed to return to clinic.
Solutions Provided by Participants
Staff and patient participants in the study were requested to provide feasible solutions
to address the identified barriers. The solutions of all participants, staff and patients, are
summarized below to minimize repetition of solutions.

UDS and In-Person Visits
Two staff participants suggested the elimination of the UDS requirement, and a third
staff participant reported that STEP should be more flexibility around UDS especially among
non-White patients due to the negative feelings the UDS may provoke. A staff participant
reported in-person visits should be eliminated while two staff participants suggested greater
flexibility in transitioning in-person visits to phone visits. One staff participant and two patient
participants suggested extending clinic hours and adding additional clinic operation days.

Transportation and Location
Two staff participants reported The STEP Clinic must develop an accessible
transportation support system for patients while another staff participant reported that the
STEP Clinic should move to a location that is reflective of the patient population served. One
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staff suggested greater flexibility in transitioning in-person visits to phone visits while another
participant stressed the need for buprenorphine clinics closer to patients’ homes.

Pharmacy and Prescription
A staff participant reported patients should be provided with longer prescriptions to
minimize trips to the pharmacy. This staff participant also reported that The STEP Clinic should
establish a pharmacy within the clinic where patients can pick up their prescription instead of
having to visit another pharmacy. Another staff participant reported a need to develop better
relationships with pharmacies frequented by STEP patients and request patient feedback to
identify problematic locations (pharmacies) or individuals (staff).

STEP Staff
Three staff participants reported a need for more diverse staff who could relate to nonWhite patients and have deeper cultural understanding. A staff participant also suggested
employing multilingual staff to ameliorate the language barriers experienced at The STEP Clinic.
Three staff participants discussed the importance of providing continuous education about
caring for patients of color with substance use disorder to all providers and staff. A staff
participant suggested that providers should be educated not to judge patients on whether
patients take their buprenorphine or other non-prescribed substances. A patient participant
reported STEP staff should learn how to trust Black patients since the lack of trust creates a
negative experience for patients and deters patients from treatment.

Patient Feedback
Five staff participants reported the need to develop an improved system to obtain
continuous feedback from patients to improve services, address patient concerns, and resolve
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issues and challenges. One staff participant reported that patients could be more successful if
staff worked with them to understand the patients’ needs and priorities.

Outreach and Collaboration
Five staff participants and four patient participants reported that outreach to non-White
organizations and communities should be improved. One staff participant suggested
collaborating with organizations such as People of Color Against Aids Network (POCAAN) and
Seattle Indian Center/Chief Seattle Club. The organizations provide marginalized communities
in the King County area with resources of services and community programs. Two staff
participants reported that The STEP Clinic should collaborate with Entre Hermanos, a non-profit
organization that provides disease prevention, support services, education, and advocacy to the
Latinx LGBTQ community. One staff participant noted that Entre Hermanos is located in the
same building as The STEP Clinic, yet no partnership was established with the organization. One
staff participant suggested employing patients who regularly access services on an outreach
team to inform other individuals with substance use disorder about the clinic’s services. Three
patient participants reported that they learned about The STEP Clinic through word of mouth.
Four of the patient participants reported that their community would benefit from STEP
services, but most people are unfamiliar with buprenorphine or unaware of the existence of
The STEP Clinic. Those patient participants stressed the importance of community outreach.

Structural Changes
Two staff participants reported the presence of systemic issues that must be addressed
at a policy level. One staff participant reported there is only so much the STEP staff can
accomplish alone. This staff participant stressed that change must come from the
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administrative level and without administrative support, STEP staff will have limited success in
implementing structural changes.

Other Suggestions
Three staff participants discussed the importance of offering housing, employment, and
mental health resources to patients. A staff participant suggested that the clinic space should
be more welcoming to patients by providing more comfortable seating, allowing patients to
spend more time in the clinic lobby, and making the clinic more accessible to patients with
mobility impairments. This staff participant reported that the building’s lift is very inaccessible
to patients and in order for patients to access the entrance, they must have a phone to request
access from the clinic. The staff participant also suggested providing services at patients’ homes
to eliminate barriers to transportation. A patient participant suggested providing higher quality
snacks for patients waiting in the lobby.
Discussion
The aim of this study was to identify, and address barriers experienced at The STEP
Clinic by non-White patients. This study found that barriers discussed in the literature: clinic
location, lack of clinician cultural literacy, stigmatization, and prescription affordability, are
experienced by non-White patients at The STEP Clinic according to STEP staff and patients. The
sections below will discuss the differences and similarities of the barriers reported by the
patients, staff, and literature and discuss solutions provided by patient and staff participants of
the study and the literature.
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Transportation and Location
Contrary to the STEP staff participants, the majority of patient participants reported the
location of The STEP Clinic was convenient. Nonetheless, as previously stated in the literature
review, buprenorphine clinics are predominantly located in US counties with a greater density
of White residents than Black/African American or Hispanic/Latinos (Goedel et al., 2020). Staff
participants recognized that The STEP Clinic is located in a gentrified area that is not reflective
of the majority of STEP’s patient population who come from lower socioeconomic backgrounds.
Therefore, many STEP patients are unable to afford to live close to the clinic. A study found that
telehealth is necessary to close the gap of MOUD and reduce mortality after Covid-19 (Wang,
2021). This study supports the staff participants’ suggestion of utilizing phone or virtual visits to
conduct follow up appointments instead of in-person visits which eliminates transportation and
location barriers. Staff participants’ suggestion of establishing a transportation system for
patients is also supported by a study conducted by Chaiyachati, (2018) which found that noshow rates for primary care appointments decreased after the implementation of a ride-share
based transportation support system. Transitioning in-person visits to phone visits may be a
more feasible solution than developing a transportation system since this solution requires no
additional resources.
Payment and Insurance
Similar to transportation/location, payment and insurance was reported as a barrier
more frequently by staff participants than patient participants. The literature supports a staff
participant’s concerns about the higher prevalence of uninsured non-White people compared
to their White counterparts (Yang, 2021). Solutions were not provided by patients or staff
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participants. However, a study suggested healthcare coverage can increase among eligible
Medicaid patients if they are provided with enrollment assistance by qualified and trained staff
(Artiga et al., 2016). STEP staff can help assist patients with basic insurance issues such as
enrollment and connect patients with additional insurance resources if needed. This will require
spending additional time with patients but may reduce the payment and insurance barriers and
increase the insurance rate among non-White patients at STEP.
Clinic Environment and Staff
The frequency that clinic environment/staff was reported as a barrier experienced by
non-White STEP patients contrasted greatly between patient and staff participants. Seven out
of eight staff participants reported this factor to be a barrier compared to one patient
participant. When asked to expand about their experience, patient and staff participants
discussed judgement, stigmatization, and distrust of non-White patients specifically Black
patients by providers, shortage of a diverse staff, and fear of healthcare providers involving law
enforcement or taking a punitive approach to non-White patients’ care compared to their
White counterparts.
These barriers reported by the patient and staff participants have also been reported in
the literature. Shortage of Black/African American and Hispanic/Latino buprenorphine
prescribers has caused additional difficulty for non-White patients’ experience when accessing
buprenorphine compared to White individuals due to White healthcare providers
misunderstanding or ignoring cultural context (Chau, 2020). Staff and patient participants
suggested employing staff with diverse cultural backgrounds that are representative of the
patient population served. SAMHSA (2020) supports this suggestion reporting that an increase
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of Black/African American and Hispanic/Latino providers can help bridge cultural gaps in
healthcare. When recruiting new hires, The STEP Clinic must seriously take into consideration
employing qualified non-White healthcare providers. This is a feasible solution that can help
alleviate some of the barriers non-White patients experience with White healthcare providers.
Staff participants’ recommendation of employing multilingual staff to ameliorate
language barriers and provide staff with continuous education on culturally competent and
compassionate care of patients of color with OUD are supported by the literature and can help
address barriers non-White patients experience at the clinic and by staff (Chau, 2020; Madras
et al., 2020; Psychiatry & Behavioral Health Learning Network, 2019). Educational modules and
training should be implemented for all new and current staff members of STEP. SAMHSA (2020)
recommends A Treatment Improvement Protocol: Improving Cultural Competence published by
SAMHSA as a tool to improve cultural competency and address implicit racial biases,
judgement, and stigmatization of non-White patients. This is a free tool that can be accessed
online, and therefore requires no additional resources or funds to implement. Updated and
new modules, workshops, and training that focus on providing care to patients of color with
OUD should be further looked into by The STEP Clinic and offered to STEP providers and staff.
Mandatory Appointments and Clinic Hours
The number of staff and patient participants who reported that mandatory
appointments and clinic hours as barriers experienced by non-White patients was very similar.
Half of both patients and staff participants reported mandatory appointments as a barrier while
five staff participants and four patient participants reported clinic hours a barrier to
buprenorphine. Patient participants discussed the difficulties of showing up to in-person
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appointments due to poor childcare accommodations and work schedules that conflict with
limited clinic hours, while staff participants discussed barriers caused by mandatory urinary
drug screens (UDS) during in-person visits. The literature review supports staff participants’
suggestion of transitioning in-person visits to phone visits to eliminate barriers caused by
transportation and in-person appointments barriers such as childcare accommodations (Wang,
2021). A study conducted by Pytell and Rastegar (2021) found that UDS cause feelings of
distrust, shame, and stigmatization among patients with substance use disorder further
validating the staff participants’ concerns about UDS. Although the study does not support the
total elimination of UDS, it does recommend healthcare providers to stop routine UDS for
patients receiving MOUD and instead adopt “targeted UDS” which is requesting UDS from
patients who can benefit from it such as patients exhibiting potential toxic effects from an
unknown substance, help guide initiation of OUD treatment, or for patients who may benefit
from positive reinforcement of UDS (Pytell & Rastegar, 2021). The STEP Clinic’s implementation
of “targeted UDS” instead of routine UDS may be a feasible solution to address the negative
experience patients face during in-person visits and would require no additional resources. The
utilization of phone visits instead of in-person visits is also another feasible solution for patients
with access to mobile phone who are unable to make their in-person appointments due to
various barriers.
Stigmatization from Community
Similar to most categories, stigmatization from community members was reported as a
barrier by staff participants more frequently than patient participants. In fact, all staff
participants reported this category to be a barrier compared to half of the patient participants.
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Studies have found that non-White people with substance use disorder experience
greater stigmatization by society and healthcare providers compared to their White
counterparts due to their minority racial status, negative racial representations, and racial
stereotyping (Madras et al., 2020 & SAMHSA, 2020). However, non-White people with
substance use disorder also experience stigma from their own communities due to a lack of
understanding of substance use disorder as a disease and the misunderstanding of treatment
options (SAMHSA, 2020).
Staff and patient participants also discussed internalized stigma as a barrier non-White
patient experience at The STEP Clinic. This barrier has also been reported in the literature. A
study found that internalized, anticipated, and enacted stigma are barriers to buprenorphine
and methadone treatment especially among racial minority communities (Anvari et al., 2022).
The study states reducing the stigma surrounding buprenorphine and methadone is crucial to
improving MOUD outcomes.
Patients and staff participants did not provide solutions that address the stigmatization
non-White patients experience from their communities or their internalized stigma. However, a
study suggests the first step to addressing misinformation and reducing stigma is by mobilizing
trusted community leaders to discuss stigmatized health issues (SAMHSA, 2020). This requires
outreach, which is discussed in a later section. Another study stresses the importance of
focusing on the role of language and how it can reinforce negative perceptions about opioid use
disorder (National Academies of Medicine, 2019). The study recommends avoiding terms such
as “substance abuser” or “medication assisted treatment” and instead use terms such as
“person with substance use disorder” and “pharmacotherapy” respectively which have been
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shown to produce more positive association. Language used at the clinic can shape a patient’s
perception of self, substance use, and treatment. This reinforces the importance of continuous
education on management and care of patients with substance use disorder as stated in the
previous section.
Pharmacy
Although both patients and staff participants reported pharmacy as a barrier
experienced by non-White patients at STEP, this barrier was reported more frequently by staff
participants than patient participants. Both staff and patient participants reported poor
treatment by pharmacy staff when non-White patients fill buprenorphine prescription. As
previously stated, the literature reports that clinicians, pharmacists, and staff have stigmatized
attitudes towards people with substance use disorder and towards medication for opioid use
disorder (Madras et al., 2020). In fact, Burgess et al. (2021) reported that pharmacists and
pharmacy technicians are the most frequent perpetrators of stigmatizing patients with opioid
use disorder. These findings alongside the racial stigma and racial stereotyping non-White
patients experience can create a significant barrier to accessing buprenorphine (SAMHSA,
2020).
Staff participants recommended providing patients with a higher quantity of
buprenorphine to reduce pharmacy visits and opening a pharmacy at The STEP Clinic. One staff
participant suggested developing better relationships with pharmacies frequented by STEP
patients and requesting patient feedback to identify problematic pharmacies and staff. The
literature supports the suggestion of improving relationships between pharmacists and
providers. Cooper et al. (2020) recommends conveying community forums for pharmacists and
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providers to resolve conflicts over buprenorphine access, discuss clear prescribing and
dispensing guidelines, and provide education from both providers and pharmacists about
buprenorphine. The study suggests this may build common standards, enhance trust between
the two professions, and improve understanding of best practice. The study also reports
continuing education on stigma reduction is necessary for all professions. Although hosting a
community forum with other pharmacies would be very beneficial, it will require many
resources including time, funding, and additional staffing to take on this project. Feasible
solutions to address poor treatment of patients with substance use disorder by pharmacy staff
were not found in the literature. Nonetheless, the staff participants suggestion of requesting
feedback to identify the pharmacies where patients experience poor treatment, and the
perpetrating staff should be considered by The STEP Clinic. Providers can avoid sending
prescriptions to the identified pharmacies or follow up with management about the poor
treatment STEP patients endure. This solution will not require additional funds but will require
staff time.
Other Issues
Five staff participants and five patient participants reported the presence of other issues
that create barriers to non-White patients at STEP to accessing their buprenorphine.
Lack of outreach and collaboration with other organizations that center non-White
communities was the most reported barrier among staff participants. Internalized shame was
the most common barrier patient participants reported. Internalized shame was addressed in a
previous section. SAMHSA, (2020) discusses the importance of outreach by highlighting that
providing buprenorphine at a clinic is not effective without outreach and community relations.
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Multiple staff participants listed organizations they believe The STEP Clinic should foster
partnerships with to expand services to non-White patients. The organizations mentioned were
People of Color Against Aids Network (POCAAN), Seattle Indian Center, Chief Seattle Club, and
Entre Hermanos. SAMHSA (2020) supports this feasible solution stating that developing multisectoral, diverse community partnership and involvement is crucial in prevention, treatment,
and recovery strategies.
Dissemination
Findings were presented to STEP Staff via Microsoft Teams. The report was
disseminated via email to all STEP staff, stakeholders, and the clinical supervisor to review. STEP
staff agreed to review the report before a round table meeting (all staff meeting). The findings
will further be discussed during the meeting. A physical copy of the findings will also be
provided as resource to The STEP clinic.
Limitations
The sparse literature on the specific barriers non-White people experience when
accessing their buprenorphine was a limitation in this study. Another limitation was that not all
patients of color were able to participant. Patients from the Middle East/North Africa were
unable to participate in the study since their race is categorized as “White” in the census
bureau.
Limitations were also experienced upon data collection. A total of 43 patients between
2020 to 2022 met the inclusion criteria of the study. However only eight patients were reached
and consented to participate. Many patients who met the inclusion criteria did not have a
phone number documented in their EMR, changed their phone number, or their phone number
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was no longer in service. Multiple patients were incarcerated and unreachable. The patients
who did agree to participate had an overall positive experience with STEP services and the
frequency of barriers they reported was much lower than the staff participants reported
barriers (Figure 5). These findings may be explained by non-response bias which is a bias that
occurs when there is a significant difference between those who responded to interviews and
those who did not (Compton et al., 2019). The patients who participated may have
overrepresented a positive experience at The Step Clinic and patients who refused to
participate or who were not reached may have had a negative experience. To overcome these
limitations, The STEP Clinic should plan for ongoing opportunities to gather feedback from
patients as part of their routine care encounter. This will expand the sample size and therefore
present data that is more representative of the patient population.
Implications for Practice
This project aimed to identify the barriers experienced by non-White patients at STEP
and collect solutions that can be implemented by STEP to address racial disparities that
contribute to the inaccessibility of buprenorphine non-White patients experience. This project
is intended to be a guide for all STEP providers and staff and to help providers and staff
recognize the presence of racial disparities at The STEP Clinic, understand the barriers
experienced by non-White patients, use this project as a resource when discussing racial
disparities at The STEP Clinic, and provide a list of solutions that can be implemented to
improve non-White patients’ accessibility to buprenorphine. Advanced registered nurse
practitioners, registered nurses, and physicians are extremely important patient advocates due
to their direct care of patients at The STEP Clinic. It is important for these healthcare providers
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to review the barriers and solutions discussed in this study to determine direct actions they can
take to improve their care of non-White patients, discuss these barriers with patients, discuss
other barriers that were not mentioned in this study with patients, and to advocate for policy
change by leadership that can support improving access to buprenorphine to non-White
patients.
This project should not come to a halt once these barriers and solutions are reviewed
and discussed. Providers and staff must advocate for leadership support to implement longterm solutions that will ease and improve care of non-White patients at The STEP Clinic. It is
essential for leadership to be onboard. Without policy change by leadership, STEP staff are
limited to what can be achieved to address barriers and increase accessibility.
Constant feedback from patients must be received to determine accessibility
improvements and to identify additional barriers that were not revealed in this study. The
enrollment and retention rate of non-White STEP patients’ post-implementation should be
acquired and compared to the pre-implementation rate to determine if addressing the
identified barriers affected enrollment and retention rates at STEP. Finally, healthcare providers
from other organizations can utilize this study to review potential barriers their non-White
patients may experience in other healthcare facilities.
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Appendix A
Patient Semi-Structured Interview Script:
Hello,
My name is Maye. I am a nurse and nurse practitioner student working with the STEP Clinic.
I am calling you because you were a patient of our and I am working on a project to improve
suboxone accessibility at the STEP Clinic to people who identify as non-White. I would love to
hear about your experience at STEP so we can improve our service. Would you be interested in
completing a five-minute interview? It would not impact your medical care at STEP in any way.
No: That’s totally fine! If you don’t have the time right now, we can always schedule a time
when I call you back. But if you’re not interested, that is okay!
-

Not interested.
Yes, lets schedule a time!

Before we start the interview, I do want to let you know that I will be not be documenting your
name or address. The STEP providers and staff will not know that you took part in this study.
You do not have to disclose any details of your medical history, current or past substance use,
or involvement with law enforcement/the justice system if you do not wish too. You can also
stop the interview at any time, and it will have no effect on the services you receive from STEP.
Do I have your consent to proceed with the interview?
Semi-Structured Interview – Patients
1. How long have you been a STEP patient?
2. How is/was your experience receiving your Suboxone prescription (rx) at STEP?
3. What are some factors that make it easy to access your Suboxone rx at STEP?
No barriers
4. What are some challenges or difficulties you experience in accessing your suboxone rx
at STEP?
5. Do you believe any of the following have created challenges in obtaining your
prescription? If yes, please explain.
a. Transportation – Location of clinic. Difficulty coming in to clinic.
b. Payment/Insurance – Difficulty affording suboxone rx
c. Mandatory appointments with the STEP provider in order to receive rx – Missed
appointments, explain.
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d. Clinic environment/staff – Feeling judged, misunderstood, or frustrated by STEP
providers or staff
i. IF YES:
a. How would you describe your relationship with the STEP
staff (provider, nurse, clinic coordinator, patient care
navigator)?
b. Do you feel welcomed at the STEP Clinic? Please explain.
c. Have you experienced language or cultural barriers at
STEP? Please explain.
e. Clinic hours – work or other responsibilities conflict with clinic hours
f. Stigmatization – feeling judged by community, friends, family
g. Pharmacy – Issues presented at pharmacy
h. Other issues – Inability to store medication, meds regularly stolen
6. How can we improve your experience at the STEP Clinic?
7. Would you recommend the STEP clinic to other community members? Please explain.
8. Do you have any other thoughts, questions, or comments?
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Appendix B
Staff Questionnaire:
DNP Project STEP Staff Survey: Identifying and Addressing Racial Disparities at STEP’s Suboxone
Clinic
Data from March 2020 shows that over 70% of STEP patients identify as White while 12.57% identified
as Black, 6.68% American Indian, 3.91% multiracial and 1.70% Asian. The literature shows that nonWhite communities have been greatly impacted by substance use disorder (SUD) however are less likely
to receive buprenorphine treatment. One study found that in 2018, 1.2 million non-Hispanic Blacks were
estimated to have opioid misuse (Chau, 2020). However, between 2012 and 2015, 12.7 million of
buprenorphine prescriptions were received by White patients while only 363,000 buprenorphine
prescriptions were received by other races/ethnicities (Lagisetty et al., 2019).
The purpose of this project is to identify and address factors at the STEP clinic that may be causing
barriers to patient of color. This survey is anonymous.
By completing this questionnaire, you are consenting to participant in the study. Based on your
experience:
1. Do you believe patients who identify as non-White experience greater barriers in

accessing their Suboxone rx at the STEP clinic? Please explain.
2. What are some of the challenges you believe non-White patients experience in

accessing their rx?
3. In your experience working with patients, do you believe any of the following have

created challenges for non-White patients in obtaining their Suboxone rx? Please
select the boxes that apply:









Transportation – Location of clinic. Difficulty coming in to clinic.
Payment/Insurance – Difficulty affording Suboxone rx
Mandatory appointments with the STEP provider in order to receive rx – Missed
appointments, explain.
Clinic environment/staff – Feeling judged, misunderstood, or frustrated by STEP providers or
staff
Clinic hours – work or other responsibilities conflict with clinic hours
Stigmatization – feeling judged by community, friends, family
Pharmacy – Issues presented at pharmacy
Other issues – Inability to store medication, meds regularly stolen, etc.

4. Please expand on the option(s) you selected above.
5. How do you think these challenges/difficulties can be improved?
6. Any other thoughts, questions, or comments?
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